{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:03Z","timestamp":1789556403152,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03391-5","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:08:29Z","timestamp":1761984509000},"page":"5857-5868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Perspectives on Switching Patients with Multiple Sclerosis from Anti-CD20 Therapy to Cladribine Tablets from USA-Based Advanced Practice Providers: A Podcast"],"prefix":"10.1007","volume":"42","author":[{"given":"Christen F.","family":"Kutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cortnee","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"3","key":"3391_CR1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316\u201334.","journal-title":"J Neurol"},{"key":"3391_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661882","volume":"12","author":"S Brancati","year":"2021","unstructured":"Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in multiple sclerosis: are we ready for regulatory approval? Front Immunol. 2021;12:661882.","journal-title":"Front Immunol"},{"key":"3391_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","volume":"13","author":"JH Yang","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926.","journal-title":"Front Neurol"},{"issue":"6","key":"3391_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.13215","volume":"289","author":"F Piehl","year":"2021","unstructured":"Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289(6):771\u201391.","journal-title":"J Intern Med"},{"issue":"12","key":"3391_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285\u201399.","journal-title":"CNS Drugs"},{"issue":"6","key":"3391_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s40120-023-00532-2","volume":"12","author":"C Watson","year":"2023","unstructured":"Watson C, Thirumalai D, Barlev A, Jones E, Bogdanovich S, Kresa-Reahl K. Treatment patterns and unmet need for patients with progressive multiple sclerosis in the United States: survey results from 2016 to 2021. Neurol Ther. 2023;12(6):1961\u201379.","journal-title":"Neurol Ther"},{"key":"3391_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.msard.2017.11.013","volume":"19","author":"P Rieckmann","year":"2018","unstructured":"Members of the MS in the 21st Century Steering Group, Rieckmann P, Centonze D, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19:153\u201360.","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"3391_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17101725","volume":"17","author":"E D\u2019Amico","year":"2016","unstructured":"D\u2019Amico E, Patti F, Zangh\u00ec A, Zappia M. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int J Mol Sci. 2016;17(10):1725.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3391_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab229","volume":"3","author":"J Graf","year":"2021","unstructured":"Graf J, Leussink VI, Soncin G, et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 2021;3(4):fcab229.","journal-title":"Brain Commun"},{"issue":"2","key":"3391_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7224\/1537-2073-13.2.57","volume":"13","author":"M Hoogs","year":"2011","unstructured":"Hoogs M, Kaur S, Smerbeck A, Weinstock-Guttman B, Benedict RH. Cognition and physical disability in predicting health-related quality of life in multiple sclerosis. Int J MS Care. 2011;13(2):57\u201363.","journal-title":"Int J MS Care"},{"issue":"1","key":"3391_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12883-023-03423-z","volume":"24","author":"HH Le","year":"2024","unstructured":"Le HH, Ken-Opurum J, LaPrade A, Maculaitis MC, Sheehan JJ. Exploring humanistic burden of fatigue in adults with multiple sclerosis: an analysis of US national health and wellness survey data. BMC Neurol. 2024;24(1):51.","journal-title":"BMC Neurol"},{"issue":"2","key":"3391_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","volume":"89","author":"DM Wingerchuk","year":"2014","unstructured":"Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225\u201340.","journal-title":"Mayo Clin Proc"},{"key":"3391_CR13","doi-asserted-by":"publisher","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron G, Larochelle C, Arbour N, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol. 2023;14:1197212.","journal-title":"Front Neurol"},{"key":"3391_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.647811","volume":"12","author":"J Hillert","year":"2021","unstructured":"Hillert J, Magyari M, Soelberg S\u00f8rensen P, et al. Treatment switching and discontinuation over 20\u00a0years in the big multiple sclerosis data network. Front Neurol. 2021;12:647811.","journal-title":"Front Neurol"},{"issue":"7","key":"3391_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","volume":"3","author":"A Gajofatto","year":"2015","unstructured":"Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545\u201355.","journal-title":"World J Clin Cases"},{"issue":"3","key":"3391_CR16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s13311-021-01048-z","volume":"18","author":"ES Frisch","year":"2021","unstructured":"Frisch ES, Pretzsch R, Weber MS. A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20-yet progress continues. Neurotherapeutics. 2021;18(3):1602\u201322.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"3391_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10100758","volume":"10","author":"D Florou","year":"2020","unstructured":"Florou D, Katsara M, Feehan J, Dardiotis E, Apostolopoulos V. Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab. Brain Sci. 2020;10(10):758.","journal-title":"Brain Sci"},{"key":"3391_CR18","unstructured":"OCREVUS (ocrelizumab) [package insert]. South San Francisco: Genentech, Inc.; 2024."},{"key":"3391_CR19","unstructured":"KESIMPTA (ofatumumab) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation; 2024."},{"key":"3391_CR20","unstructured":"BRIUMVI (ublituximab-xiiy) [package insert]. New York: TG Therapeutics, Inc.; 2024."},{"issue":"3","key":"3391_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"3391_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"key":"3391_CR23","unstructured":"MAVENCLAD (cladribine) [package insert]. Rockland: EMD Serono, Inc.; 2024."},{"issue":"5","key":"3391_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"key":"3391_CR25","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594\u2013604.","journal-title":"Mult Scler"},{"key":"3391_CR26","doi-asserted-by":"publisher","first-page":"1379538","DOI":"10.3389\/fimmu.2024.1379538","volume":"15","author":"\u00d3 Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez \u00d3, S\u00f6rensen PS, Comi G, et al. Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review. Front Immunol. 2024;15:1379538.","journal-title":"Front Immunol"},{"issue":"suppl","key":"3391_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jns.2019.10.1122","volume":"405","author":"G Giovannoni","year":"2019","unstructured":"Giovannoni G, Rammohan K, Cook S, et al. Efficacy of cladribine tablets 3.5\u00a0mg\/kg in patients with relapsing multiple sclerosis aged above and below 45\u00a0years; clarity and clarity extension. J Neurol Sci. 2019;405(suppl):177\u20138.","journal-title":"J Neurol Sci"},{"issue":"17","key":"3391_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"key":"3391_CR29","unstructured":"Kutz C, Aldridge J, Evans E. Transitioning patients with relapsing multiple sclerosis from anti-CD20 therapy to cladribine tablets in the United States. Presented at the Consortium of Multiple Sclerosis Centers. May\u00a029\u2013June 1, 2024, Nashville, DMT16."},{"key":"3391_CR30","unstructured":"Kutz C, Aldridge J, Evans E. Switching patients with multiple sclerosis from anti-CD20 or S1P receptor modulators to cladribine tablets in the United States: a real-world age-based analysis. Presented at ECTRIMS, September 18\u201320, 2024, Copenhagen, eP1725."},{"key":"3391_CR31","doi-asserted-by":"publisher","first-page":"1274194","DOI":"10.3389\/fneur.2023.1274194","volume":"14","author":"T Spelman","year":"2023","unstructured":"Spelman T, Magyari M, Butzkueven H, et al. Predictors of treatment switching in the big multiple sclerosis data network. Front Neurol. 2023;14:1274194.","journal-title":"Front Neurol"},{"key":"3391_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755","volume":"61","author":"I Rauma","year":"2022","unstructured":"Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61:103755.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"3391_CR33","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, et al. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. 2023;270(7):3553\u201364.","journal-title":"J Neurol"},{"issue":"7","key":"3391_CR34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","volume":"22","author":"S Arena","year":"2024","unstructured":"Arena S, Chisari CG, Toscano S, et al. Real-world effectiveness of cladribine for patients with multiple sclerosis: a Sicilian multicentric experience (Rewind study). Curr Neuropharmacol. 2024;22(7):1271\u201383.","journal-title":"Curr Neuropharmacol"},{"key":"3391_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.5389","author":"D O\u2019Neill","year":"2020","unstructured":"O\u2019Neill D, Hodgkinson S. Short-term efficacy and safety outcomes after switching from anti-CD20 DMTs to cladribine in a real-world setting (5389). Neurology. 2020;94(15_supplement).","journal-title":"Neurology"},{"key":"3391_CR36","unstructured":"Negroski D, Sellers S, Khiabani A, Khiabani D. Real-world experience switching from high-efficacy infusions to cladribine tablets. Presented at ECTRIMS, October 26\u201328, 2022, Amsterdam, EP1055."},{"issue":"4","key":"3391_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","volume":"11","author":"V Meca-Lallana","year":"2022","unstructured":"Meca-Lallana V, Garc\u00eda Dom\u00ednguez JM, L\u00f3pez Ruiz R, et al. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther. 2022;11(4):1475\u201388.","journal-title":"Neurol Ther"},{"issue":"17","key":"3391_CR38","doi-asserted-by":"publisher","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","volume":"99","author":"I Roos","year":"2022","unstructured":"Roos I, Malpas C, Leray E, et al. Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis. Neurology. 2022;99(17):e1926\u201344.","journal-title":"Neurology"},{"key":"3391_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103076","volume":"53","author":"K Bigaut","year":"2021","unstructured":"Bigaut K, Cohen M, Durand-Dubief F, et al. How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP). Mult Scler Relat Disord. 2021;53:103076.","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"3391_CR40","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394.","journal-title":"J Neurol"},{"issue":"4","key":"3391_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1212\/WNL.0000000000002887","volume":"87","author":"G Wang","year":"2016","unstructured":"Wang G, Marrie RA, Salter AR, et al. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology. 2016;87(4):365\u201374.","journal-title":"Neurology"},{"issue":"4","key":"3391_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","volume":"8","author":"L Freeman","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes. 2021;8(4):497\u2013508.","journal-title":"Drugs Real World Outcomes"},{"issue":"7","key":"3391_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21(7):676\u201386.","journal-title":"J Med Econ"},{"issue":"1","key":"3391_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/2772432817666220412110720","volume":"18","author":"VP Stamatellos","year":"2023","unstructured":"Stamatellos VP, Papazisis G. Safety and monitoring of the treatment with disease-modifying therapies (DMTs) for multiple sclerosis (MS). Curr Rev Clin Exp Pharmacol. 2023;18(1):39\u201350.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"9","key":"3391_CR45","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0175","volume":"12","author":"V Bhan","year":"2023","unstructured":"Bhan V, Clift F, Baharnoori M, et al. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res. 2023;12(9):e220175.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"3391_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40120-023-00573-7","volume":"13","author":"S Stoll","year":"2024","unstructured":"Stoll S, Costello K, Newsome SD, Schmidt H, Sullivan AB, Hendin B. Insights for healthcare providers on shared decision-making in multiple sclerosis: a narrative review. Neurol Ther. 2024;13(1):21\u201337.","journal-title":"Neurol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03391-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:16Z","timestamp":1763132656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03391-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03391-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christen Kutz has received consulting fees from Alexion, BMS, Biogen, EMD Serono, Genzyme, and Teva. Cortnee Roman has no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by either of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}